Drugs / EVARREST™ Sealant Matrix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02227992 | Jul 2014 → Oct 2021 | hemorrhagic disease, liver disorder | Ethicon, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVARREST Sealant Matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02227992 ↗ |